Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Substrate reduction therapy for glycosphingolipid storage disorders.

R H Lachmann1, F M Platt

  • 1Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Hills Road, Cambridge, UK. rhl20@cam.ac.uk

Expert Opinion on Investigational Drugs
|February 28, 2001
PubMed
Summary

Substrate reduction therapy offers a new way to treat glycosphingolipid storage disorders by slowing down GSL synthesis. Clinical trials show N-butyldeoxynojirimycin (NB-DNJ) is effective in Gaucher

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A master protocol to investigate a novel therapy acetyl-L-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosidoses, and ataxia telangiectasia.

Trials·2021
Same author

White matter integrity correlates with cognition and disease severity in Fabry disease.

Brain : a journal of neurology·2020
Same author

NPC1 regulates ER contacts with endocytic organelles to mediate cholesterol egress.

Nature communications·2019
Same author

European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience.

European journal of neurology·2017
Same author

Childhood Pompe disease: clinical spectrum and genotype in 31 patients.

Orphanet journal of rare diseases·2016
Same author

Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study.

Journal of inherited metabolic disease·2014

Area of Science:

  • Biochemistry
  • Genetics
  • Pharmacology

Background:

  • Glycosphingolipid (GSL) lysosomal storage disorders result from enzyme deficiencies in GSL catabolism.
  • Pathological accumulation of GSL substrates occurs within cellular lysosomes.
  • Current treatments are limited, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To review the development and efficacy of substrate reduction therapy (SRT) for GSL lysosomal storage disorders.
  • To highlight N-butyldeoxynojirimycin (NB-DNJ) as a key agent in SRT.
  • To present evidence supporting SRT as a viable treatment approach.

Main Methods:

  • Development of N-butyldeoxynojirimycin (NB-DNJ), an imino sugar inhibitor of ceramide-specific glucosyltransferase.
  • In vitro studies using a Gaucher's disease model.

Related Experiment Videos

  • In vivo studies using knockout mouse models of Tay-Sachs and Sandhoff diseases.
  • Clinical trials in patients with Type 1 Gaucher's disease.

    • Main Results:

    • NB-DNJ demonstrated efficacy in slowing glycolipid accumulation in vitro and in vivo models.
    • Administration of NB-DNJ to Sandhoff mice delayed neurological disease onset and progression.
    • Clinical trials in Type 1 Gaucher's disease patients showed safety and efficacy of NB-DNJ.

    Conclusions:

    • Substrate reduction therapy is a promising approach for treating GSL lysosomal storage disorders.
    • NB-DNJ provides a proof-of-principle for SRT in various GSL storage diseases.
    • SRT offers a potential therapeutic strategy for a range of lysosomal storage disorders.